FDA approves Pillar Biosciences’ cancer diagnostic test
Photo | Courtesy of Google
Pillar Biosciences located in Natick
Natick biotech firm Pillar Biosciences received premarket approval from the U.S. Food and Drug Administration for its oncoRevea Dx Lung and Colon Cancer Assay, according to a press release Thursday.
The product is a companion diagnostic test detecting somatic mutations in DNA derived from non-small cell lung cancer and colorectal cancer tumors.
With FDA approval, this product can be used by any lab conducting NGS testing, making precision medicine accessible to all cancer patients, the release stated.
“We are committed to providing high quality and accurate IVD tests to enable better treatment decisions for cancer patients,” said Gang Song, founder and CEO at Pillar Biosciences, in the press release.
Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics with operations in both Natick, MA and Shanghai, China.
WBJ Web Partners
Most Recent
Most Recent
0 Comments